XML 46 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Summary of Significant Accounting Policies - Additional Information (Detail)
 1 Months Ended 6 Months Ended
May 31, 2020
USD ($)
$ / shares
shares
Aug. 31, 2019
USD ($)
Jun. 30, 2020
USD ($)
Segment
shares
Dec. 31, 2019
shares
Jun. 30, 2019
USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]          
Number of operating segment | Segment     1    
Cash, cash equivalents and marketable securities     $ 200,700,000    
Principal amount including interest paid in kind     $ 180,900,000    
Debt maturity date     Dec. 31, 2023    
Common stock, shares issued | shares     109,503,000 83,871,000  
Inventory reserve     $ 0   $ 0
Maximum          
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]          
Expected period of payment to be received     1 year    
Public Offering          
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]          
Common stock, shares issued | shares 16,100,000        
Proceeds from issuance initial public offering $ 75,400,000 $ 65,600,000      
Sale of stock, price per share | $ / shares $ 5.00        
HEPLISAV-B®          
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]          
Minimum age approved for vaccine prevention of infection caused     18 years